Inotek Pharmaceuticals Initiates Multiple-Dose Phase 2 Clinical Trial Of INO-8875 In Patients With Glaucoma
LEXINGTON Mass., - June 17, 2010
Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that it has initiated dosing in a multiple-dose Phase 2 clinical trial to evaluate the efficacy and safety of its novel eye-drop INO-8875 in patients with glaucoma.